NCMT Technique and Jodhpur Technique and Excimer Laser in Treatment of Non Vitiligo Leucoderma

N/ANot Yet RecruitingNCT07662915

Al-Azhar University22 enrolled

Overview

This study aims to compare the efficacy and safety of Melanocyte Keratinocyte Transplantation Procedure (MKTP) combined with 308-nm excimer laser versus Jodhpur technique combined with 308-nm excimer laser in the treatment of stable non-vitiligo leukoderma. Twenty-two patients with stable depigmented lesions will be enrolled. In each patient, two comparable lesions will be treated using different techniques. Clinical outcomes including percentage of repigmentation, color match, time to onset of repigmentation, complications, and histological changes will be assessed during follow-up to determine the optimal surgical treatment approach for non-vitiligo leukoderma.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Leukoderma

Interventions

Autologous melanocyte-keratinocyte cell suspension prepared using enzymatic separation and applied to a dermabraded recipient site.

Jodhpur TechniquePROCEDURE

Autologous non-cultured epidermal cell transfer technique using dermabraded donor skin particles applied directly to the recipient site without enzymatic processing

308-nm Excimer LaserDEVICE

Excimer laser therapy initiated approximately 14 days after surgery, administered twice weekly for 12-16 weeks with dose adjustment according to erythema response

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18 to 60 years. * Clinically diagnosed stable non-vitiligo leukoderma. * Stable lesion(s) for at least 6 months with no progression. * Inadequate response to conventional medical therapy. * Presence of two comparable lesions * Willingness to participate and provide written informed consent. Exclusion Criteria: * Vitiligo or suspected active vitiligo. * History of keloid or hypertrophic scar formation. * Active infection at donor or recipient sites. * Bleeding disorders or anticoagulant therapy that cannot be safely discontinued. * Pregnancy or lactation. * Immunosuppression or uncontrolled systemic disease. * Inability to comply with follow-up visits. * Unrealistic expectations regarding treatment outcome.

Outcomes

Primary Outcomes

Mean Percentage Repigmentation of Target Lesions

Time frame: 6 months

Secondary Outcomes

Time to Onset of Repigmentation

Time frame: Up to 6 months

Color Match Assessment

Time frame: 6 months

Central Contacts

Mohamed Mahmoud

CONTACT

+201091865997 mas912m@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.